里昂发表报告，预期京东健康去年下半年面对高基数及消费放缓的挑战，估计去年第四季收入按年下跌7.5%，下半年则持平于264亿元人民币，新冠相关产品销售额按年料跌逾50%，非新冠产品销售保持25%至30%增长；下半年经调整息税前盈利料按年升36%，至13亿元人民币，受惠毛利率扩张。该行相信艰难环境将会持续至今年上半年，但下半年增长料加快，今年全年收入料增长约20%，利润率温和扩张，将今明两年经调整盈测分别下调4%及11%，目标价由65港元下调至50港元，维持买入评级。
里昂降京东健康目标价至50港元 下调今明两年经调整盈测
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.